At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
mepolizumabdrug
Likely dose
mepolizumab 0.55 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219)
In Brief
A Phase 2 clinical trial evaluating mepolizumab for Oesophagitis, Eosinophilic. Completed, enrolled 84 participants across 29 sites in 4 countries.
Detailed Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOesophagitis, Eosinophilic
CountriesAustralia, Canada, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2006
Enrollment StartSep 2006
Primary CompletionNov 2008
TodayJul 2026
First PostedJul 31, 2006
Enrollment StartSep 11, 2006
Primary CompletionNov 25, 2008
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.9 years ago
Interventions
mepolizumabdrug
Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.